Dosage regimes in the prescription of heroin and other narcotics to chronic opioid addicts in Switzerland - Swiss national cohort study

European Addiction Research

Volumn 10, Issue 1, 2004, Pages 41-48

  Gschwend, Patrick ^a,f   Rehm, Jürgen ^a,e   Blättler, Richard ^a   Steffen, Thomas ^a   Seidenberg, André ^a   Christen, Stephan ^c   Bërki, Christoph ^d   Gutzwiller, Felix ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Uetikon am See   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY OF TORONTO   (Canada)

^f Institut fur Sucht und Gesundheitsforschung Zurich   (Switzerland)

Author keywords

Addiction; Diacetylmorphine; Dosage; Heroin; Heroin prescription; Methadone; Morphine; Pharmacology; Switzerland

Indexed keywords

DIAMORPHINE; METHADONE; OPIATE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; HEALTH PROGRAM; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NARCOTIC DEPENDENCE; OPIATE ADDICTION; OUTPATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; SWITZERLAND;

ADMINISTRATION, ORAL; ADULT; AMBULATORY CARE; CLINICAL TRIALS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; FEMALE; HEROIN; HEROIN DEPENDENCE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHADONE; MORPHINE; NARCOTICS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PRESCRIPTIONS, DRUG; SUBSTANCE ABUSE DETECTION; SUBSTANCE ABUSE, INTRAVENOUS; SWITZERLAND;

EID: 0344305633     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073725     Document Type: Article

References (26)

1. Klingemann H: Harm Reduction and Abstinence: Swiss Drug Policy at a Time of Transition; in Klingemann H, Hunt G (eds): Drug Treatment Systems in an International Perspective. Thousand Oaks, SAGE Publications, 1999, pp 94-111.
2. Swiss Federal Office of Public Health: The Swiss Drug Policy. A Four-fold Approach with Special Consideration of the Medical Prescription of Narcotics. Bern, Swiss Federal Office of Public Health, 1999.
3. Klingemann H: Drogenpolitik und Drogenbehandlung - 'Sonderfall Schweiz'? Wien Z Suchtforsch 1998;21:19-37.
4. Uchtenhagen A, Gutzwiller F, Dobler-Mikola A, Steffen T, Rihs-Middel M (eds): Prescription of Narcotics for Heroin Addicts - Main Results of the Swiss National Cohort Study. Basel, Karger, 1999.
5. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A: Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. Lancet 2001;358:1417-1420.
6. Bammer G, Crawford D, Dance P, Ostini R, Stevens A: Controlled heroin availability in Australia? How and to what end? Int J Addict 1995;30:991-1007.
7. Fischer B: Heroinabhängigkeit, -behandlung und -politik in Kanada: Geschichte, Gegenwart und Perspektiven für einen Heroin- Verschreibungsversuch; in Westermann B, Bellmann G, Jellinek C (eds): Heroinverschreibung - Wirkungen und Nebenwirkungen. Weinheim, Deutscher Studienverlag, 1999.
8. Van den Brink W, Hendriks V, Van Ree J: Medical co-prescription of heroin to chronic, treatment-resistant methadone patients in the Netherlands. J Drug Issues 1999;29:587-608.
9. Ball JC, Ross A: The Effectiveness of Methadone Maintenance Treatment. New York, Springer, 1991.
10. Caplehorn J, Bell J: Methadone dosage and retention of patients in maintenance treatment. Med J Aust 1991;154:195-199.
11. D'Aunno T, Vaughn T: Variations in methadone treatment practices: Results from a national study. JAMA 1992;267:253-258.
12. Loimer N, Schmid R: The use of plasma levels to optimize methadone maintenance treatment. Drug Alcohol Depend 1992;30:241-246.
13. Caplehorn J, Mc Neil D, Kleinbaum D: Clinic policy and retention in methadone maintenance. Int J Addict 1993;1:73-89.
14. Grabowski J, Rhoades H, Elk R, Schmitz J, Creson D: Methadone dosage, cocaine and opiate abuse. Am J Psychiatry 1993;150:675.
15. Strain E, Stitzer M, Liebson I, Bigelow G: Dose response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993; 119:23-27.
16. Gardner R, Connell PH: One year's experience in a drug-dependence clinic. Lancet 1970;ii:455-458.
17. Mitcheson M: Drug clinics in the 1970s; in Strang J, Gossop M (eds): Heroin Addiction and Drug Policy. The British System. New York, Oxford University Press, 1994, pp 178-191.
18. Hartnoll RL, Mitcheson MC, Batterby A, Brown G, Ellis M, Fleming P, et al: Evaluation of Heroin Maintenance in Controlled Trial. Arch Gen Psychiatry 1980;37:877-884.
19. Strang J, Sheridan J: Heroin prescribing in the 'British System' of the mid-1990s: Data from the 1995 national survey of community pharmacies in England and Wales. Drug Alcohol Rev 1997;16:7-16.
20. McCusker C, Davies M: Prescribing drug of choice to illicit heroin users: The experience of a U.K. community drug team. J Subst Abuse Treat 1996;13:521-531.
21. Metrebian N, Shanahan W, Wells B, Stimson GV: Feasibility of prescribing injectable heroin and methadone to opiate-dependent drug users: Associated health gains and harm reductions. Med J Aust 1998;168:596-600.
22. Haemmig R, Tschacher W: Effects of high-dose heroin versus morphine in intravenous drug users: A randomised double-blind crossover study. J Psychoactive Drugs 2001;33:105-110.
23. Perneger TV, Giner F, del Rio M, Mino A: Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998;317:13-18.
24. Ladewig D, Hug I, Stohler R, Battegay M, Gyr K, Erb P, et al: A randomised trial with methadone, morphine and heroin in the treatment of opiate dependence. Basel, Department of Psychiatry, University of Basel, 1997.
25. Seidenberg A, Honegger U: Methadon, Heroin und andere Opioide. Medizinisches Manual für die ambulante opioidgestützte Behandlung. Bern, Huber, 1998.
26. Seidenberg A, Peng M, Custer R: Prinzipien der sicheren Opioidverordnung; in Rihs-Middel M, Jacobshagen N, Seidenberg A (eds): Ärztliche Verschreibung von Betäubungsmitteln. Praktische Umsetzung und wichtigste Ergebnisse. Bern, Hans Huber, 2002, pp 375-383.